

Application Serial No. 09/618,361
Amendment dated September 10, 2003
Reply to Office Communication dated July 10, 2003



Listing of Claims:

1. (Previously Canceled)
2. (Previously Canceled)
3. (Previously Canceled)
4. (Previously Canceled)
5. (Previously Canceled)
6. (Previously Canceled)
7. (Previously Canceled)
8. (Previously Canceled)
9. (Previously Canceled)
10. (Previously Canceled)

RECEIVED
SEP 17 2003
TECH CENTER 1600/2900

Application Serial No. 09/618,361
Amendment dated September 10, 2003
Reply to Office Communication dated July 10, 2003

11. (Previously Canceled)

12. (Previously Canceled)

13. (Previously Canceled)

14. (Previously Canceled)

15. (Previously Canceled)

16. (Previously Canceled)

17. (Previously Canceled)

18. (Previously Canceled)

19. (Previously Canceled)

20. (Previously Canceled)

Application Serial No. 09/618,361
Amendment dated September 10, 2003
Reply to Office Communication dated July 10, 2003

21. (Previously Canceled)

22. (Previously Canceled)

23. (Previously Canceled)

24. (Previously Canceled)

25. (Previously Canceled)

26. (Previously Canceled)

27. (Previously Canceled)

28. (Previously Canceled)

29. (Previously Canceled)

30. (Previously Canceled)

Application Serial No. 09/618,361
Amendment dated September 10, 2003
Reply to Office Communication dated July 10, 2003

31. (Previously Canceled)

32. (Previously Canceled)

33. (Previously Canceled)

34. (Previously Canceled)

35. (Previously Canceled)

36. (Previously Canceled)


37. (Previously Canceled)

38. (Previously Canceled)

39. (Previously Canceled)

40. (Currently Amended) A therapeutic composition comprising:

a therapeutically effective amount of a compound having the formula:



wherein:

each R1 and R2, independently, is H, C1-C12 alkyl, C6-C18 aryl, C1-C18 acyl, C7-C18 aralkyl, C7-C18 alkaryl or a dihydrotrigonellinate group;

A1 is a D or L-amino acid selected from the group consisting of Cys, Leu, Dap, Trp, Gln, a tethered amino acid with an indole ring, Phe, Hyp, a derivative of Trp selected from the group consisting of N-Me-Trp, nor Trp, beta Me-Trp, 2-Cl-Trp, and 5-X-Trp where X is selected from the group consisting of CN, Br, NH₂, COOH, CH₂NH₂ and CH₂-CH₂NH₂; CαMe-Trp, CαMe-Gln, Des-amino-Trp, Pyr, Bth, Nal, Tcc, Asn, Nva, Abu, Tyr, Tic-OH, Phe, Tip, and Dip;

A2 is a D or L-amino acid selected from the group consisting of Cys, Trp, Arg, Nα-Me-Arg, CαMe-Arg, Orn, Cit, hArg(R)₂, where R is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, or alkylaryl, Lys-ε-NH-R, where R is selected from the group consisting of alkyl, aryl, aralkyl, or alkylaryl; A3 is a D or L-amino acid selected from the group consisting of Glu, N-Me-Tyr, CαMe-Tyr,

Tic-OH, Tic, Dip, Trp, Phe, des-carboxylic-Tyr (tyramine), and Tyr-(R), where R is

hydrogen or a lipophilic group;

W is -OH, -N-R₃R₄, or OR₅, where R₃, R₄, and R₅, independently, is H, C1-

C12 alkyl, C6-C18 aryl, Cl-C12 acyl, C7-C18 aralkyl, or C7-C18 alkaryl, or a

pharmaceutically acceptable salt thereof; and

each bond between two amino acids or amino acid derivatives, represented by a

dash ("-"), can be either a peptide bond or a pseudopeptide bond; and

a pharmaceutically acceptable carrier substance;

wherein said therapeutically effective amount of said compound in said

~~composition being capable of attenuating~~ attenuates Neuropeptide Y (NPY) mediated
~~or NPY-like~~ physiological responses.

41. (Currently Amended) The compound of claim 40, wherein said compound has a
formula ~~selected from the group~~ consisting of N- α -Ac-Trp-Arg-Tyr-NH₂.

42. (Previously Added) The compound of claim 40, wherein said compound is
conjugated to a carrier selected from the group consisting of cationized albumin and
polylysine.

43. (Currently Amended) The compound of claim 40, wherein the said bond between two amino acids or amino acid derivatives is selected from the group consisting of C(O)NH, CH₂NH, CH₂-S, CH₂-O, CH₂-CH₂, CH₂-CO, and CH₂ CH₂.

44. (Previously Added) The compound of claim 43, wherein a pseudopeptide bond is positioned between A1 and A2.

45. (Previously Added) The compound of claim 44, wherein a pseudopeptide bond is positioned between A2 and A3.

46. (Canceled)

47. (Previously Amended) The composition of claim 40, wherein said composition is in the form of a pill, tablet, or capsule for oral administration.

48. (Previously Amended) The composition of claim 40, wherein said composition is in the form of a liquid for oral administration.

49. (Previously Amended) The composition of claim 40, wherein said composition is in the form of a liquid for nasal administration as drops or spray.

50. (Previously Amended) The composition of claim 40, wherein said composition is in the form of a liquid for intravenous, subcutaneous, parenteral, or intraperitoneal administration.

51. (Previously Amended) The composition of claim 40, wherein said composition is in the form of a biodegradable sustained- release composition for intramuscular administration.

52. (Previously Amended) The composition of claim 40, wherein said composition includes a lipophilic salt and is suitable for administration in the form of an oil emulsion or dispersion.